about
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cellsAchieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis.Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis.FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy.A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.Curry-assisted diagnosis in the rheumatology clinic.Co-stimulatory blockade as therapy for rheumatoid arthritis.Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell ArteritisA Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis.The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy.Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.What is the impact of giant cell arteritis on patients' lives? A UK qualitative study.A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group.Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group.Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients.Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study.Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: The Patient Perspective.Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.Dilatation of the thoracic aorta and increased arterial stiffness is common in patients with giant cell arteritis - preliminary findings from a cardiac magnetic resonance study.Preliminary concurrent validity of the Fitbit-Zip and ActiGraph activity monitors for measuring steps in people with polymyalgia rheumatica.Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors.Response to: 'A relationship between extracapsular involvement and response to steroid treatment in polymyalgia rheumatica: too soon to conclude?' by Yang et al.Vasculitis syndromes: Dealing with increased vascular risk and mortality in GCA.Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study.Faculty of 1000 evaluation for ARTICLE RETRACTED: CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in NarcolepsyInflammation and vascular occlusion in giant cell arteritisToward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working GroupImproving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled TrialsCharacteristics of patients with giant cell arteritis who experience visual symptoms
P50
Q28249199-4DDA26E5-B570-4D8C-A80A-34F76AC67C39Q31151181-126CDE2E-D13B-494E-935D-5A203681C54CQ33846363-269550D8-3B1B-459F-939A-A00B4BA56331Q34123499-EDDA8E3D-BFDE-47AC-850C-91FCF94CBFA4Q35266391-0E2C266D-8DF2-401C-84AA-4A303C044123Q35683702-2B62F3C2-B7AE-4E5B-B905-6DEB857C691AQ36262484-DC153562-D774-4DBD-A634-BD65589BF1AAQ36653502-4CA8C174-4C1E-4FDA-9FB7-C043567C9F03Q37575470-54A2D496-9D37-4100-AE72-91C7E3D5213AQ38184442-0578D2DA-A6B7-4B00-9621-B86165CCFB9FQ38244799-05E4F339-23BC-432B-AF95-362A9DB3E267Q38436495-00b8de10-44d7-33d0-f182-31f344c4b960Q38633673-E33EC1D9-D5B4-4E23-81BD-EC3CA0CEC461Q38637549-30F44095-2BC5-48C6-814A-A4EF2A8BA488Q38862663-9D15DEE3-E7E3-412B-86EC-C0A10180F965Q39040255-17992323-1D09-4B6A-823A-21B74B3EB31CQ39301083-B69C9F0A-5302-43D3-9F7A-A25C178E944AQ43197430-2A14AE9C-BFB0-4925-A32A-5D917C7F9C70Q47419344-66CFC94B-E1B5-4476-9D3B-96A7BD5D7112Q47683751-B978D02F-7ED3-492B-ABC1-6DC62F166DF3Q48508157-CFC8127D-87E4-43FF-8EDA-E6A8DCF1DD3FQ49882268-57DE511B-7CFF-4333-9BAD-5154A47F1FE2Q50085775-7EF20BA7-9C63-47A6-AB7F-0EF4138473C1Q50513958-41A96631-F732-4296-B649-A7621F1432BFQ52818364-CAF5D597-DA79-40B4-AA1C-E64EE17713C5Q52840052-829B0643-B713-4EB2-91DC-C5A3B8CF9C12Q52843951-612F9088-2CF2-4AE5-9EEA-35F6223D0FEAQ56833256-FC1D1109-F643-49AA-9F36-8E0C765A4C23Q58451777-8AC9ECB9-DD14-4744-9952-DB52DBD32374Q91062142-7A91415F-9DFE-410C-A14D-D42BB73A5127Q91062354-D4173EE4-A0D1-4A10-8D46-A9065A1C277DQ92804350-2EFABB86-A00A-4A83-8ADD-882D856C337E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-ca
researcher
@en-gb
ymchwilydd
@cy
հետազոտող
@hy
name
Sarah L Mackie
@br
Sarah L Mackie
@ca
Sarah L Mackie
@cs
Sarah L Mackie
@da
Sarah L Mackie
@de-at
Sarah L Mackie
@de-ch
Sarah L Mackie
@et
Sarah L Mackie
@eu
Sarah L Mackie
@fi
Sarah L Mackie
@gd
type
label
Sarah L Mackie
@br
Sarah L Mackie
@ca
Sarah L Mackie
@cs
Sarah L Mackie
@da
Sarah L Mackie
@de-at
Sarah L Mackie
@de-ch
Sarah L Mackie
@et
Sarah L Mackie
@eu
Sarah L Mackie
@fi
Sarah L Mackie
@gd
altLabel
Sarah Mackie
@br
Sarah Mackie
@ca
Sarah Mackie
@cs
Sarah Mackie
@cy
Sarah Mackie
@da
Sarah Mackie
@de
Sarah Mackie
@de-at
Sarah Mackie
@de-ch
Sarah Mackie
@en
Sarah Mackie
@en-ca
prefLabel
Sarah L Mackie
@br
Sarah L Mackie
@ca
Sarah L Mackie
@cs
Sarah L Mackie
@da
Sarah L Mackie
@de-at
Sarah L Mackie
@de-ch
Sarah L Mackie
@et
Sarah L Mackie
@eu
Sarah L Mackie
@fi
Sarah L Mackie
@gd
P106
P1153
7003543269
P2031
2003-01-01T00:00:00Z
P2038
Sarah_Mackie
P21
P213
0000 0004 2703 4219
P31
P496
0000-0003-2483-5873